{
    "medicine_id": "f23a747e2d6d011bea236f9b6d1aefd0fdac2499",
    "platform_id": "DB09031",
    "metadata": {
        "name": "Impavido 50 mg 1 Capsule",
        "composition": "50 mg 1 Miltefosine",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of mucosal caused by Leishmania braziliensis cutaneous caused by L braziliensis L guyanensis and L panamensis and visceral leishmaniasis caused by L donovani In comparing Leishmania drug susceptibility it has been found that L donovani is the most susceptible to miltefosine while L major is the least susceptible Off label use includes treatment of free living amebae FLA infections unlabeled use CDC 2013",
            "contraindications": {
                "disease": "Preclinical reproductive toxicity studies in animals showed fetal death and teratogenicity at doses lower than the recommended human dose Use of miltefosine during pregnancy is therefore strictly contraindicated and contraceptive use is mandatory for females of child bearing age during therapy and for 5 months afterwards Preclinical studies additionally showed impaired female and male fertility in animals Stevens Johnson syndrome has been reported therefore therapy should be discontinued if an exfoliative or bullous rash occurs during treatment",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Little is known about the clinical pharmacodynamics of miltefosine and other antileishmanial drugs",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB00266",
                        "description": "The therapeutic efficacy of Dicoumarol can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB00498",
                        "description": "The therapeutic efficacy of Phenindione can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB00682",
                        "description": "The therapeutic efficacy of Warfarin can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB00946",
                        "description": "The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB01418",
                        "description": "The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB03410",
                        "description": "The therapeutic efficacy of 4 hydroxycoumarin can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB04665",
                        "description": "The therapeutic efficacy of Coumarin can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB08496",
                        "description": "The therapeutic efficacy of R warfarin can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB08794",
                        "description": "The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB13136",
                        "description": "The therapeutic efficacy of Fluindione can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB13275",
                        "description": "The therapeutic efficacy of Clorindione can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB13347",
                        "description": "The therapeutic efficacy of Diphenadione can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB13451",
                        "description": "The therapeutic efficacy of Tioclomarol can be increased when used in combination with Miltefosine"
                    },
                    {
                        "drugbank-id": "DB14055",
                        "description": "The therapeutic efficacy of S Warfarin can be increased when used in combination with Miltefosine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}